CHINA - CROSS-BORDER MERGERS AND ACQUISITIONS MARKET TRENDS & OUTLOOK

CHINA – CROSS-BORDER MERGERS AND ACQUISITIONS MARKET TRENDS & OUTLOOK

Global financial markets are shifting with geopolitical tensions, increased interest rates, and protectionism, causing global investors to be cautious. China`s post-pandemic recovery is one of the main global opportunities and will have implications for almost any industry. As China is recovering from the aftermath of the pandemic, reemerging on the global M&A arena, international government-led initiatives are key for understanding how investors and MNCs are dealing with China going forward.

We invite you to join us for an informative event focused on cross-border mergers and acquisitions in China. Our experts from the ARC Group will provide deep insights into both inbound and outbound cross-border M&A trends. The event will cover the current market overview in China, including an economic snapshot and M&A from a policy point of view. In addition, we will discuss the Belt and Road Initiative and Made in China 2025.

The event will also highlight key opportunities and challenges when pursuing cross-border transactions related to China. Our panel of experienced experts will share their expertise and insights, highlighting key strategies for success in the Chinese market.

This event is ideal for business leaders, investors, and policy-makers interested in learning more about cross-border mergers and acquisitions in China. Join us for an opportunity to network with industry leaders and gain valuable insights into the challenges and opportunities of cross-border transactions in China.

Date & Time: 4th April 2023

8:00AM – 10:00AM

Agenda:

8:00AM – 8:30AM Registration & Breakfast

8:30AM – 9:30AM Presentation & Q&A

9:30AM – 10:00AM Breakfast & Mingling

Venue: 5th floor, Andaz Hotel Shanghai (Xintiandi, 88 Songshan Road)

上海安达仕酒店5楼花园亭台

SPEAKERS
  • Ulrik Hoksnes Karlsen

    Vice President at M&A

  • Isabella Zuo

    Senior Associate at M&A

SPONSORS AND PARTNERS

ORGANIZER

SPONSOR

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission